Other therapies for BPH patients: Desmopressin, anti-cholinergic, anti-inflammatory drugs, and botulinum toxin

World Journal of Urology

Volumn 24, Issue 4, 2006, Pages 383-388

  Azzouzi, Abdel Rahmène ^b   Fourmarier, Marc ^c   Desgrandchamps, Francois ^d   Ballereau, Charles ^e   Saussine, Christian ^f   Haillot, Olivier ^g   Lukacs, Bertrand ^h   Devonec, Marian ⁱ   Taille, Alexandre ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^g UNIVERSITY HOSPITAL OF TOURS   (France)

^h HÔPITAL TENON   (France)

ⁱ HOSPICES CIVILS DE LYON   (France)

Author keywords

Anti cholinergic; Anti diuretic hormone; Botulinum toxin; BPH; Inflammation

Indexed keywords

ANTIDIURETIC AGENT; ANTIINFLAMMATORY AGENT; ARGIPRESSIN[1 DEAMINO]; BOTULINUM TOXIN; CHOLINERGIC RECEPTOR BLOCKING AGENT;

ARTICLE; HUMAN; MALE; PROSTATE HYPERTROPHY;

ANTI-INFLAMMATORY AGENTS; ANTIDIURETIC AGENTS; BOTULINUM TOXINS; CHOLINERGIC ANTAGONISTS; DEAMINO ARGININE VASOPRESSIN; HUMANS; MALE; PROSTATIC HYPERPLASIA;

EID: 33748104248     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-006-0095-x     Document Type: Article

References (29)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132:474-479
2. Girman CJ, Jacobsen SJ, Tsukamoto T, Richard F, Garraway WM, Sagnier PP, Guess HA, Rhodes T, Boyle P, Lieber MM (1998) Health-related quality of life associated with lower urinary tract symptoms in four countries. Urol Mar 51(3):428-436
3. Van Kerrebroeck P, Abrams P, Chaikin D, Donovan J, Fonda D, Jackson S, Jennum P, Johnson T, Lose GR, Mattiasson A, Robertson GL, Weiss J (2002) International continence society. The standardization of terminology in nocturia: Report from the standardization subcommittee of the International Continence Society. BJU Int 90(Suppl 3):11-15
4. Asplund R, Aberg H (1991) Diurnal variation in the levels of antidiuretic hormone in the elderly. J Intern Med 229(2):131-134
5. Cugini P, Battisti P, Di Palma L, Cavallini M, Pozzilli P, Scibilia G, Letizia C, Cassisi A, Cioli AR, Marino B (1992) Secondary aldosteronism documented by plasma renin and aldosterone circadian rhythm in subjects with kidney or heart transplantation. Ren Fail 14(1):69-76
6. Mattiasson A, Abrams P, Van Kerrebroeck P, Walter S, Weiss J (2002) Efficacy of desmopressin in the treatment of nocturia: A double-blind placebo-controlled study in men. BJU Int 89(9):855-862
7. Lose G, Mattiasson A, Walter S, Lalos O, van Kerrebroeck P, Abrams P, Freeman R (2004) Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol 172(3):1021-1025
8. Abrams P, Mattiasson A, Lose GR, Robertson GL (2002) The role of desmopressin in the treatment of adult nocturia. BJU Int 90(Suppl 3):32-36
9. Le Normand (2005) Comment je prescris le Minirin chez l'adulte. Progrès FMC 15(2):2-3
10. Peters TJ, Donovan JL, Kay HE, Abrams P, de la Rosette JJ, Porru D, Thuroff JW (1997) The International Continence Society "Benign Prostatic Hyperplasia" Study: The botherosomeness of urinary symptoms. J Urol 157(3):885-889
11. Hyman MJ, Groutz A, Blaivas JG (2001) Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol 166(2):550-552
12. Greenland JE, Brading AF (2001) The effect of bladder outflow obstruction on detrusor blood flow changes during the voiding cycle in conscious pigs. J Urol 165(1):245-248
13. Harrison SC, Hunnam GR, Farman P, Ferguson DR, Doyle PT (1987) Bladder instability and denervation in patients with bladder outflow obstruction. Br J Urol 60(6):519-522
14. Mirone V, Imbimbo C, Sessa G, Palmieri A, Longo N, Granata AM, Fusco F (2004) Correlation between detrusor collagen content and urinary symptoms in patients with prostatic obstruction. J Urol 172(4 Pt 1):1386-1389
15. Seki N, Karim OM, Mostwin JL (1992) Changes in electrical properties of guinea pig smooth muscle membrane by experimental bladder outflow obstruction. Am J Physiol 262(5 Pt 2):F885-F891
16. Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB (2004) Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 94(6):817-820
17. Chapple CR (2004) Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: An overview for the practising clinician. BJU Int 94(5):738-744
18. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G (2003) Combination treatment with an alpha-blocker plus an anti-cholinergic for bladder outlet obstruction: A prospective, randomized, controlled study. J Urol 169(6):2253-2256
19. Kaplan SA, Walmsley K, Te AE (2005) Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 174(6):2273-2275
20. Roehrborn C, Kaplan SA, Noble WD, Lucia MS, Slawin KM, McVary KT, Kusek JW, Nyberg LM (2005) The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH: Results from the MTOPS study. J Urol AUA #1277
21. Araki T, Yokoyama T, Kumon H (2004) Effectiveness of a nonsteroidal anti-inflammatory drug for nocturia on patients with benign prostatic hyperplasia: A prospective non-randomized study of loxoprofen sodium 60 mg once daily before sleeping. Acta Med Okayama 58(1):45-49
22. Di Silverio F, Bosman C, Salvatori M, Albanesi L, Proietti Pannunzi L, Ciccariello M, Cardi A, Salvatori G, Sciarra A (2005) Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Eur Urol 47(1):72-78
23. Doggweiler R, Zermann DH, Ishigooka M, Schmidt RA (1998) Botox-induced prostatic involution. Prostate 37(1):44-50
24. Maria G, Destito A, Lacquaniti S, Bentivoglio AR, Brisinda G, Albanese A (1998) Relief by botulinum toxin of voiding dysfunction due to prostatitis. Lancet 352(9128):625
25. Kuo HC (2003) Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction. J Urol 170(5):1908-1912
26. Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A (2003) Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: Results of a randomized, placebo-controlled study. Urology 62(2):259-264
27. Kuo HC (2005) Prostate botulinum A toxin injection - an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 65(4):670-674
28. Larson TR, Huidobro C, Acevedo C, Mynderse L, Larson B (2005) Intraprostatic Injection of Botulinum Toxin in the treatment of symptomatic LUTS, including sequential MRIs for accurate changes in size of the prostate. J Urol, AUA San Antonio, abstract 1386
29. Guercini F, Giannantoni A, Bard RL, Brinsida G, Cadeddu F, Maria G, Rosi P, Pajoncini C, Porena M (2005) Inraprostatic botulin toxin injection in patients with severe Benign Prostatic Hyperplasia a multicenter feasibility study. J Urol, AUA San Antonio, abstract 1387